; and (B) input from patient groups and medical provider associations. (f) Rule of construction Nothing in this section shall be construed to limit requirements for investigations, as described in section 505B(a)(3) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355c(a)(3) ), of molecularly targeted pediatric cancer drugs for which orphan designation has been granted under section 526 of such Act ( 21 U.S.C. 360bb ). 3. Reauthorizing the program for pediatric studies of drugs Section 409I(d)(1) of the Public Health Service Act ( 42 U.S.C. 284m(d)(1) ) is amended in paragraph (1) by striking $25,000,000 for each of fiscal years 2023 through 2027 and inserting $50,000,000 for each of fiscal years 2023 through 2027 . 4. Ensuring completion of pediatric study requirements (a) Equal accountability for pediatric study requirements Section 505B(d)(2) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355c(d)(2) ) is amended by striking (except that the drug or biological product shall not be subject to action under section 303) . (b) Conforming amendments Section 303(f)(4)(A) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 333(f)(4)(A) ) is amended by striking or 505–1 and inserting 505–1, or 505B . (c) Transition rule The Secretary of Health and Human Services shall take no enforcement actions under section 303 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 333 ) for failures described in section 505B(d) of such Act ( 21 U.S.C. 355c(d) ) before the date this is 180 days after the date of enactment of this Act. 5. FDA report on PREA enforcement Section 508(b) of the Food and Drug Administration Safety and Innovation Act ( 21 U.S.C. 355c–1(b) ) is amended— (1) in paragraph (11), by striking the semicolon at the end and inserting , including an assessment of the appropriateness of deferrals and deferral extensions granted for such products and an evaluation of compliance with deadlines provided for in such deferrals and deferral extensions; ; (2) in paragraph (15), by striking and at the end